Procainamide induced sustained monomorphic ventricular tachycardia in a patient with benign premature ventricular complexes.
A 59-year old female with history of benign ventricular ectopy who developed sustained monomorphic ventricular tachycardia (VT) during therapy with procainamide is reported. The tachycardia occurred 24 hours after institution of procainamide without any other evidence of drug toxicity or QT prolongation. When procainamide was withheld, VT resolved completely and no arrhythmia could be induced by programmed ventricular stimulation. When the patient was rechallenged with procainamide at therapeutic level, sustained monomorphic VT was initiated reproducibly by programmed ventricular stimulation. Without antiarrhythmic therapy, patient has been asymptomatic and free of recurrent VT after a follow-up of 9 months. This case: Demonstrates that procainamide may cause the first emergence of sustained monomorphic VT in a patient with no previous history of VT; and Emphasizes the utility of programmed ventricular stimulation in providing direct evidence for drug mediated exacerbation of the ventricular arrhythmia.
A K
AK
Bhandari
P K
PK
Au
S H
SH
Rahimtoola
D002037:Bundle-Branch Block / Q000139:chemically induced; D005117:Cardiac Complexes, Premature / Q000188:drug therapy*; D002304:Cardiac Pacing, Artificial; D004562:Electrocardiography; D005260:Female; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D011342:Procainamide / Q000009:adverse effects* / Q000627:therapeutic use; D013610:Tachycardia / Q000139:chemically induced*
D011342:Procainamide